Last 31 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.81 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | 40.47 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.61 | 2.46 | 5.29 | 5.04 | 2.31 | 3.86 | 2.38 | 1.58 | 1.83 | 0.94 | 1.72 | 1.34 | 1.57 | 2.39 | 2.36 | 2.91 | 1.98 | 2.11 | 1.03 | 1.17 | 8.81 |
| — | -36.1% | +122.0% | +218.8% | +26.2% | +309.6% | +38.3% | +18.0% | +16.6% | -60.7% | -27.0% | -54.0% | -20.9% | +13.6% | +129.5% | +147.9% | -77.5% | -75.3% | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | 100.0% | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | -1770.0% | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | -1538.4% | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -41.3% | -14.3% | -9.6% | -7.7% | -9.4% | -19.5% | -14.1% | -11.4% | -7.4% | -8.6% | -7.1% | -8.7% | -6.1% | -6.6% | -4.4% | -7.8% | -9.9% | -6.5% | -5.2% | -15.8% | -22.6% |
| — | +27.0% | +32.3% | +32.2% | -27.8% | -126.5% | -100.1% | -31.2% | -21.4% | -31.4% | -60.7% | -11.6% | +38.4% | -1.0% | +15.8% | +50.8% | +56.5% | +96.4% | +74.2% | +17.7% | -24.4% | |
| ROA | -36.9% | -12.7% | -8.6% | -7.0% | -8.2% | -16.0% | -12.2% | -10.4% | -6.9% | -8.3% | -6.8% | -8.2% | -5.7% | -6.1% | -4.0% | -7.1% | -8.9% | -5.9% | -4.8% | -13.8% | -15.8% |
| — | +20.6% | +29.5% | +32.9% | -19.2% | -94.1% | -80.4% | -26.5% | -20.5% | -34.4% | -67.8% | -15.9% | +36.1% | -3.7% | +15.2% | +48.5% | +43.4% | +95.3% | +67.8% | +7.7% | -13.0% | |
| ROIC | -41.3% | -14.4% | -9.6% | -7.7% | -9.4% | -20.3% | -16.4% | -12.6% | -7.8% | -8.6% | -7.3% | -9.0% | -6.3% | -6.6% | -4.8% | -7.7% | -9.1% | -12.7% | -728.4% | -318.4% | -60.7% |
| — | +29.0% | +41.6% | +38.8% | -20.4% | -135.9% | -123.8% | -41.0% | -22.9% | -29.8% | -51.5% | -17.0% | +30.7% | +47.9% | +99.3% | +97.6% | +85.0% | +97.9% | -452.8% | -37.8% | +82.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.05 | 0.06 | 0.05 | 0.05 | 0.05 | 0.11 | 0.06 | 0.05 | 0.05 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.34 |
| — | -45.4% | -9.3% | -5.7% | -5.3% | +1326.9% | +543.1% | +354.0% | +289.3% | -46.5% | -40.3% | -27.8% | -54.0% | -49.4% | -46.2% | -43.9% | -91.9% | -92.3% | -92.4% | -87.7% | +44.1% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 15.02 | 11.22 | 19.04 | 15.02 | 17.82 | 7.66 | 8.33 | 14.96 | 31.84 | 16.15 | 40.74 | 19.73 | 18.26 | 18.07 | 16.41 | 12.05 | 12.80 | 12.36 | 15.03 | 13.84 | 3.72 |
| — | +46.4% | +128.5% | +0.4% | -44.0% | -52.6% | -79.5% | -24.2% | +74.4% | -10.6% | +148.3% | +63.7% | +42.7% | +46.2% | +9.2% | -12.9% | +244.1% | +200.4% | +291.5% | +178.4% | -37.8% | |
| Quick Ratio | 15.02 | 11.22 | 19.04 | 15.02 | 17.82 | 7.66 | 8.33 | 14.96 | 31.84 | 16.15 | 40.74 | 19.73 | 18.26 | 18.07 | 16.41 | 12.05 | 12.80 | 12.36 | 15.03 | 13.84 | 3.72 |
| — | +46.4% | +128.5% | +0.4% | -44.0% | -52.6% | -79.5% | -24.2% | +74.4% | -10.6% | +148.3% | +63.7% | +42.7% | +46.2% | +9.2% | -12.9% | +244.1% | +200.4% | +291.5% | +178.4% | -37.8% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -8.96 | -20.22 | -21.20 | -359.10 | -332.18 | -75.60 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 31 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CMPX stock.
Compass Therapeutics, Inc.'s current P/E is -1.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Compass Therapeutics, Inc.'s business trajectory between earnings reports.